MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Tauopathies"

  • MDS Virtual Congress 2020

    The severity and distribution of tau pathology distinguish corticobasal degeneration and progressive supranuclear palsy

    S. Koga, N. Ghayal, S. Roemer, D. Dickson (Jacksonville, FL, USA)

    Objective: To elucidate whether the severity and distribution of tau pathology reflect the clinical presentations in progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Background:…
  • MDS Virtual Congress 2020

    Can we stage tau pathology in PSP?

    G. Kovacs, M. Lukic, D. Irwin, T. Arzberger, G. Respondek, E. Lee, D. Coughlin, A. Giese, M. Grossman, C. Kurz, C. McMillan, E. Gelpi, Y. Compta, J. van Swieten, C. Troakes, S. Al-Sarraj, J. Robinson, S. Roeber, S. Xie, V. Lee, J. Trojanowski, G. Höglinger (Phildelphia, PA, USA)

    Objective: To evaluate distribution pattern of tau pathology in different PSP clinical subtypes and develop a staging system. Background: Progressive supranuclear palsy (PSP) is a…
  • MDS Virtual Congress 2020

    18kDa Translocator Protein PET in 4-Repeat Tauopathies – A Cross-Sectional Single Center Study

    C. Palleis, J. Sauerbeck, L. Beyer, S. Harris, J. Schmitt, A. Finze, A. Nitschmann, G. Biechele, K. Boetzel, A. Danek, B. Rauchmann, M. Unterrainer, N. Albert, R. Rupprecht, P. Bartenstein, R. Perneczky, C. Haass, J. Levin, G. Hoeglinger, M. Brendel (Munich, Germany)

    Objective: The aim of this single center study was to analyse the potential of 18F-GE-180 TSPO PET as a biomarker in 4R-tauopathies. Background: The pathological…
  • 2019 International Congress

    Comparative Grey and White Matter Tau Pathology in LBD and PSP using Digital Histologic Measurements

    D. Coughlin, C. Petersen, R. Lobrovich, D. Wolk, A. Siderowf, D. Weintraub, E. Lee, J. Trojanowski, M. Grossman, D. Irwin (Philadelphia, PA, USA)

    Objective: To compare the regional distribution of cortical tau pathology between Lewy body disorders (LBD: Parkinson’s disease and dementia with Lewy bodies (DLB)) and progressive…
  • 2019 International Congress

    Drug Utilization in a Real World Cohort with Progressive Supranuclear Palsy

    G. Hoeglinger, D. Oleske, J. Zamudio, R. Diegidio, J. Holman (Munich, Germany)

    Objective: To evaluate the frequency of prescription medications commonly associated with the management of PSP in the community. Background: Progressive Supranuclear Palsy (PSP) is a…
  • 2019 International Congress

    Skin in the game: Small fiber neuropathy in Parkinson’s disease and atypical parkinsonisms.

    R. Infante, G. Rizzo, A. Incensi, C. Scaglione, S. Capellari, V. Donadio, R. Liguori (Bologna, Italy)

    Objective: The aim of our study was to compare somatic and autonomic small fiber density, through skin biopsy, in Parkinson's disease (PD) and atypical parkinsonisms…
  • 2019 International Congress

    Deciphering Corticobasal Syndrome: are clinical features and FDG-PET imaging capable of predicting amiloyd status?

    J. Parmera, A. Coutinho, A. Neto, M. Aranha, C. Ono, C. Buchpiguel, R. Nitrini, E. Barbosa, S. Brucki (São Paulo, Brazil)

    Objective: The present study aimed at establishing clinical and brain functional patterns at FDG-PET that could distinguish Corticobasal Syndrome(CBS) variants due to AD from Tau pathology based on Pittsburgh Compound…
  • 2019 International Congress

    Complement C3a receptor antagonist attenuates tau hyperphosphorylation via glycogen synthase kinase 3β signaling pathways

    JJ. Hu, T. Wang (Wuhan, China)

    Objective: To investigate the role and mechanism of C3a receptor in okadaic acid(OA) induced SH-SY5Y cells tau hyperphosphorylation model Background: Neurofibrillary tangles aggregated from hyperphosphorylated…
  • 2019 International Congress

    Heavy metals implicated in a geographical cluster of progressive supranuclear palsy induce tau accumulation and apoptotic cell death in cultured neurons

    C. Alquezar, J. Felix, E. Mccandlish, B. Buckley, D. Caparros-Lefebvre, C. Karch, L. Golbe, A. Kao (San Francisco, CA, USA)

    Objective: To test the hypothesis that certain metals may cause cellular damage suggesting tauopathy. This is an early step in testing the hypothesis that environmental…
  • 2019 International Congress

    Cortical and subcortical atrophy in typical and variant Parkinson-plus syndromes: PROSPECT-M-UK study

    N. Holland, S. Jones, J. Woodside, E. Jabbari, V. Chelban, A. Costantini, PN. Leigh, D. Burn, N. Pavese, A. Gerhard, C. Kobylecki, M. Hu, A. Church, J. Rohrer, H. Houlden, H. Morris, J. Rowe (Cambridge, United Kingdom)

    Objective: To investigate grey matter volume in typical and variant Parkinson-plus syndromes, to correlate these with disease severity, and to assess regional atrophy within disease…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 14
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley